Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer

Michela Murdocca; Francesco Torino; Sabina Pucci; Manuela Costantini; Rosamaria Capuano; Chiara Greggi; Chiara Polidoro; Giuseppina Somma; Valentina Pasqualetti; Yolande Ketchanji Mougang; Alexandro Catini; Giuseppe Simone; Roberto Paolesse; Augusto Orlandi; Alessandro Mauriello; Mario Roselli; Andrea Magrini; Giuseppe Novelli; Corrado Di Natale; Federica Carla Sangiuolo

doi:10.3390/cancers13164213

Cancers (Aug 2021)

Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer

Michela Murdocca,
Francesco Torino,
Sabina Pucci,
Manuela Costantini,
Rosamaria Capuano,
Chiara Greggi,
Chiara Polidoro,
Giuseppina Somma,
Valentina Pasqualetti,
Yolande Ketchanji Mougang,
Alexandro Catini,
Giuseppe Simone,
Roberto Paolesse,
Augusto Orlandi,
Alessandro Mauriello,
Mario Roselli,
Andrea Magrini,
Giuseppe Novelli,
Corrado Di Natale,
Federica Carla Sangiuolo

Affiliations

Michela Murdocca: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Francesco Torino: Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Sabina Pucci: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Manuela Costantini: Department of Urology, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
Rosamaria Capuano: Department of Electronic Engineering, University of Rome Tor Vergata, Via del Politecnico 1, 00133 Rome, Italy
Chiara Greggi: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Chiara Polidoro: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Giuseppina Somma: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Valentina Pasqualetti: Department of Electronic Engineering, University of Rome Tor Vergata, Via del Politecnico 1, 00133 Rome, Italy
Yolande Ketchanji Mougang: Department of Electronic Engineering, University of Rome Tor Vergata, Via del Politecnico 1, 00133 Rome, Italy
Alexandro Catini: Department of Electronic Engineering, University of Rome Tor Vergata, Via del Politecnico 1, 00133 Rome, Italy
Giuseppe Simone: Department of Urology, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
Roberto Paolesse: Department of Chemical Science and Technology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy
Augusto Orlandi: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Alessandro Mauriello: Department Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Mario Roselli: Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Andrea Magrini: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Giuseppe Novelli: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Corrado Di Natale: Department of Electronic Engineering, University of Rome Tor Vergata, Via del Politecnico 1, 00133 Rome, Italy
Federica Carla Sangiuolo: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy

DOI: https://doi.org/10.3390/cancers13164213
Journal volume & issue: Vol. 13, no. 16
p. 4213

Abstract

Read online

Renal cell carcinoma (RCC) represents around 3% of all cancers, within which clear cell RCC (ccRCC) are the most common type (70–75%). The RCC disease regularly progresses asymptomatically and upon presentation is recurrently metastatic, therefore, an early method of detection is necessary. The identification of one or more specific biomarkers measurable in biofluids (i.e., urine) by combined approaches could surely be appropriate for this kind of cancer, especially due to easy obtainability by noninvasive method. OLR1 is a metabolic gene that encodes for the Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), implicated in inflammation, atherosclerosis, ROS, and metabolic disorder-associated carcinogenesis. Specifically, LOX-1 is clearly involved in tumor insurgence and progression of different human cancers. This work reports for the first time the presence of LOX-1 protein in ccRCC urine and its peculiar distribution in tumoral tissues. The urine samples headspace has also been analyzed for the presence of the volatile compounds (VOCs) by SPME-GC/MS and gas sensor array. In particular, it was found by GC/MS analysis that 2-Cyclohexen-1-one,3-methyl-6-(1-methylethyl)- correlates with LOX-1 concentration in urine. The combined approach of VOCs analysis and protein quantification could lead to promising results in terms of diagnostic and prognostic potential for ccRCC tumors.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords